| Code | CSB-RA025833MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Bevacizumab-BVZR, designed to specifically target vascular endothelial growth factor A (VEGFA). VEGFA is a critical signaling protein that regulates angiogenesis by promoting endothelial cell proliferation, migration, and vascular permeability. This growth factor plays essential roles in both physiological processes such as wound healing and embryonic development, as well as pathological conditions including tumor angiogenesis, diabetic retinopathy, and age-related macular degeneration. Elevated VEGFA expression is strongly associated with cancer progression, as tumors exploit angiogenic pathways to establish blood supply necessary for growth and metastasis.
Bevacizumab-BVZR is an anti-VEGFA humanized IgG1 monoclonal antibody. Its binding to VEGFA on endothelial cells prevents its interaction with VEGF receptors, inhibiting angiogenesis, cutting off the nutrients and oxygen supply to the tumor, thereby suppressing the growth and metastasis of the tumor. This biosimilar antibody serves as a valuable research tool for investigating VEGFA-mediated signaling pathways, studying angiogenesis mechanisms, and developing anti-angiogenic therapeutic strategies. It enables researchers to explore vascular biology, tumor microenvironment dynamics, and potential interventions targeting pathological neovascularization.
There are currently no reviews for this product.